Welcome to our dedicated page for Caredx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on Caredx stock.
CareDx, Inc. reports developments in precision medicine for transplant patients and caregivers. The company’s updates center on non-invasive molecular testing for heart, kidney, and lung transplantation, including AlloSure, AlloMap, HeartCare, and related evidence generation for post-transplant surveillance, risk assessment, and longitudinal patient management.
CareDx news also covers operating and financial results for testing services and patient and digital solutions, product and platform launches such as VANTx clinical data analytics, clinical conference presentations, material agreements, and Nasdaq-related governance matters including inducement equity awards.
CareDx, Inc. (Nasdaq: CDNA) announced that CEO Reg Seeto has been appointed Corporate Chair of the ISHLT Foundation's Global Steering Committee. This committee aims to advance innovations in heart and lung transplantation through the "Fostering Excellence Campaign," which will fund vital research and career development awards. CareDx aims to improve outcomes for patients with advanced heart and lung disease, aligning with the ISHLT Foundation's mission. This collaboration highlights CareDx's commitment to enhancing transplant patient care.
CareDx announces the validation of its OTTR Patient Management Software for SMART on FHIR standards, enhancing interoperability in healthcare. This announcement aligns with their presentation of new data on AlloHeme and AlloCell during the Tandem Meetings from April 23-26, 2022, in Salt Lake City, Utah. These innovations are aimed at improving patient monitoring for allogeneic hematopoietic stem cell transplants and therapies. The ACROBAT study will further evaluate AlloHeme's ability in disease relapse detection, promising advancements in patient care.
CareDx, Inc. (Nasdaq: CDNA) announced its collaboration with UC Davis Health to launch a new program named Pluralist. This initiative focuses on improving organ donation and transplantation awareness in underserved communities in California. Through digital education and community engagement, the program aims to address health disparities and increase organ donations, particularly among minority populations who represent a significant share of transplant recipients. CareDx’s contribution to this project underscores its commitment to health equity in transplantation.
CareDx, Inc. (Nasdaq: CDNA) showcased its leadership at the ISHLT Annual Meeting, presenting over 25 oral presentations and posters on heart and lung transplant innovations. Key highlights include interim findings from the Surveillance HeartCare Outcomes Registry (SHORE), which underscore the effectiveness of multimodality assessments in transplant care. CareDx also introduced XenoSure and XenoMap for xenotransplantation research. The company emphasizes the importance of integrating its diagnostic tools for improved patient outcomes and reduced biopsies, demonstrating significant advancements in the field.
CareDx, Inc. (Nasdaq: CDNA) has successfully delivered over 200,000 AlloMap® and AlloSure® test results to more than 30,000 heart transplant patients, showcasing its significant role in the U.S. heart transplant community. The company has been a trusted partner since 2005, with AlloMap being the only FDA-cleared gene-expression profiling test for heart transplants. CareDx’s HeartCare platform, which integrates both AlloMap and AlloSure, is now utilized by over 90% of heart transplant centers in the U.S., reflecting a strong attachment rate of clinical adoption.
CareDx, Inc. (CDNA) announced its participation in the UNOS Transplant Management Forum from April 11-13, 2022, showcasing its TxAccess digital platform designed to expedite the pre-transplant process. The platform facilitates electronic communication and referral processing, significantly reducing errors and time spent on paper-based methods. Medical City Transplant Institute's study highlights improvements in operational workflows and patient management. CareDx's digital tools aim to enhance efficiency and patient experience throughout the transplant journey.
CareDx Hosts Innovative Symposium on Transplant Health
SOUTH SAN FRANCISCO, Calif., April 6, 2022 – CareDx, Inc. (Nasdaq: CDNA) announces its symposium, “Improved Precision with a Multimodality Approach,” at the American Society of Transplantation’s CEoT meeting, April 6-8. The event on April 7 will discuss multimodality surveillance advancements using AlloSure® dd-cfDNA and AlloMap® gene-expression profiling for kidney and lung transplants. NYU Langone Health's abstract on dd-cfDNA stability post-SARS-CoV-2 vaccination reinforces vaccine safety in kidney transplant recipients.
CareDx, Inc. (Nasdaq: CDNA) has partnered with the European Society for Organ Transplantation (ESOT) to enhance education regarding the use of donor-derived cell-free DNA (dd-cfDNA) in monitoring transplanted organ health. This collaboration aims to promote AlloSeq cfDNA, which provides insights into allograft injury and rejection risk. Both organizations emphasize the importance of non-invasive monitoring technologies for improving transplant outcomes. CareDx plans to leverage this partnership to expand the adoption of its technologies across Europe.
CareDx, Inc. (Nasdaq: CDNA) announced its partnership with the HeartBrothers Foundation to host a patient education webinar on navigating heart transplantation. This event will take place on March 31, 2022, and aims to provide insights into the transplant journey through personal stories and information on non-invasive post-transplant surveillance. CareDx highlights its commitment to supporting heart failure patients and promotes its AlloMap® Heart product, utilized by over 90% of heart transplant centers. The partnership underscores CareDx's dedication to enhancing patient education and support in the transplant community.
CareDx, Inc. (Nasdaq: CDNA) has enhanced its AlloCare® mobile app with a new “virtual roadmap” feature aimed at assisting kidney failure patients in managing the transplant waitlist process. Historically, only 13.5% of the 550,000 U.S. dialysis patients are on waiting lists, largely due to the complex requirements. The new feature, integrated with the TxAccess™ tool, allows pre- and post-transplant patients to connect with healthcare providers and track essential steps. Since its launch in 2020, AlloCare has been downloaded over 25,000 times, offering valuable health metric tracking and support.